Timur Yarovinsky, MD, PhD
Research Scientist (Cardiovascular Medicine)Cards
About
Research
Publications
2025
Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling
Kim S, Nouws J, Ruwisch J, Woodard G, Cooley J, Khoury J, Sun H, Doherty E, Piecychna M, Manning E, Kang M, Bruscia E, Wei H, Zhang Y, Yarovinsky T, Hwa J, Zacharias W, Ingram J, Lee C, Elias J, Kaminski N, Redente E, Herzog E, Prasse A, Bucala R, Sauler M. Dysregulated alveolar type 2 epithelial cell proteostasis promotes fibrogenic macrophage migration inhibitory factor–CD74 signaling. Science Translational Medicine 2025, 17: eadr2277. PMID: 41337540, DOI: 10.1126/scitranslmed.adr2277.Peer-Reviewed Original ResearchMeSH KeywordsAlveolar Epithelial CellsAnimalsAntigens, Differentiation, B-LymphocyteBleomycinDisease Models, AnimalHistocompatibility Antigens Class IIHumansIdiopathic Pulmonary FibrosisIntramolecular OxidoreductasesLungMacrophage Migration-Inhibitory FactorsMacrophagesMaleMiceMice, Inbred C57BLMice, TransgenicProteasome Endopeptidase ComplexProteostasisSignal TransductionUbiquitinConceptsIdiopathic pulmonary fibrosisMacrophage migration inhibitory factorBronchoalveolar lavage fluidPharmacological inhibition of MIFBleomycin-induced lung injury modelMouse modelPharmacological inhibitionC-X3-C motif chemokine receptor 1Human precision-cut lung slicesTransforming growth factor-b1Inhibition of macrophage migration inhibitory factorSignals to macrophagesPrecision-cut lung slicesFibrotic lung diseaseType 2 epithelial cellsAlveolar type 2 epithelial cellsChemokine receptor 1Lung injury modelMigration inhibitory factorMIF-2Study participantsUbiquitin-proteasome systemSpontaneous fibrosisPulmonary fibrosisLavage fluidImmunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity
Yang L, Yarovinsky T, Pham K, Xi Y, Lu P, Iwasaki A, Rose J, Liu C. Immunization with virus-like vesicle-based COVID-19 vaccine induces robust systemic and mucosal immunity. Npj Vaccines 2025, 10: 211. PMID: 41022870, PMCID: PMC12480480, DOI: 10.1038/s41541-025-01260-4.Peer-Reviewed Original ResearchMucosal immunityCD8+ TCD4+ TT cell responsesPrime-boost immunizationAnti-spike antibodiesBNT162b2 mRNA vaccineCOVID-19 vaccineMucosal immune responsesCOVID-19 vaccine candidatesLong-term preventionIn vivo protectionB cellsC57BL/6J miceMRNA vaccinesImmune responseAntibody levelsRNA polymeraseGlobal morbidityVaccine candidatesVSV glycoproteinReceptor-binding domainDisease severityIgA productionSARS-CoV-2EROdicating arterial thrombosis with a novel endoplasmic reticulum oxidoreductase 1α inhibitor
Yarovinsky T, Sharda A, Hwa J. EROdicating arterial thrombosis with a novel endoplasmic reticulum oxidoreductase 1α inhibitor. Molecular Therapy 2025, 33: 4682-4683. PMID: 40975058, DOI: 10.1016/j.ymthe.2025.09.012.Peer-Reviewed Original ResearchCARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer
Ahmadi E, Chiari C, Madina B, Yarovinsky T, Krady M, Chen J, Almassian B, Nakaar V, Wang K. CARG-2020 targets IL-12, IL-17, and PD-L1 pathways to effectively treat melanoma and breast cancer. Scientific Reports 2025, 15: 29649. PMID: 40804279, PMCID: PMC12350727, DOI: 10.1038/s41598-025-14750-1.Peer-Reviewed Original ResearchConceptsColorectal cancerPD-L1Oncolytic virusesBroad-spectrum efficacySystemic deliveryIL-12Accumulation of CD8+ T lymphocytesBreast cancerGenetically engineered oncolytic virusesMouse modelCD8+ T lymphocytesMouse model of melanomaTriple-negative breast cancerPD-L1 pathwayPoor tumor regressionPD-L1 expressionIL-17RA signalingModel of melanomaCytokines IL-12Colorectal cancer growthCancer immunotherapyTumor regressionT cellsSolid tumorsMultiple human cancersEnhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation
Amoako K, Mokhammad A, Malik A, Yesudasan S, Wheba A, Olagunju O, Gu S, Yarovinsky T, Faustino E, Nguyen J, Hwa J. Enhancing nucleic acid delivery by the integration of artificial intelligence into lipid nanoparticle formulation. Frontiers In Medical Technology 2025, 7: 1591119. PMID: 40589473, PMCID: PMC12206802, DOI: 10.3389/fmedt.2025.1591119.Peer-Reviewed Original ResearchNucleic acid deliveryLipid nanoparticlesAcid deliveryDesign of lipid nanoparticlesMessenger RNADeliver messenger RNAEnhancing nucleic acid deliveryLipid nanoparticle formulationImmune response modulationHematologic therapyPlatelet-related disordersNucleic acid cargoHematological treatmentNanoparticle formulationGold standardEndosomal trappingTherapeutic potentialPersonalized medicineDelivery efficiencyNanoparticle designPlateletCellular targetsResponse modulationDeliveryTransfection barriersPlatelet–Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease (Adv. Sci. 5/2025)
Zhang Y, Jia C, Guo M, Chen Q, Wen Y, Wang T, Xie Y, Fan X, Gao J, Yarovinsky T, Liu R, Jiang Z, Wang M, Zhou J, Che D, Fu L, Edelson R, Gu X, Hwa J, Tang W. Platelet–Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease (Adv. Sci. 5/2025). Advanced Science 2025, 12: 2570027. PMCID: PMC11791971, DOI: 10.1002/advs.202570027.Peer-Reviewed Original Research
2024
Platelet–Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease
Zhang Y, Jia C, Guo M, Chen Q, Wen Y, Wang T, Xie Y, Fan X, Gao J, Yarovinsky T, Liu R, Jiang Z, Wang M, Zhou J, Che D, Fu L, Edelson R, Gu X, Hwa J, Tang W. Platelet–Monocyte Aggregate Instigates Inflammation and Vasculopathy in Kawasaki Disease. Advanced Science 2024, 12: 2406282. PMID: 39665236, PMCID: PMC11792051, DOI: 10.1002/advs.202406282.Peer-Reviewed Original ResearchKawasaki diseaseCD14+ CD16+ monocytesPlatelet-monocyte aggregatesAberrant immune responseAcute febrile illnessCoronary artery aneurysmsNuclear factor-kappaBSystemic vasculitisPlatelet-monocyteProinflammatory monocytesPlatelet hyperreactivityArtery aneurysmVasculopathyFebrile illnessCytokine mediatorsHyperactive plateletsReduce inflammationPlatelet glycoproteinImmune responseInterleukin-1Platelet activationPositive feedback loopLigand 1MonocytesGrowth factorPlatelet Mitochondrial Fusion and Function in Vascular Integrity
Tyagi T, Yarovinsky T, Faustino E, Hwa J. Platelet Mitochondrial Fusion and Function in Vascular Integrity. Circulation Research 2024, 134: 162-164. PMID: 38236952, PMCID: PMC10798220, DOI: 10.1161/circresaha.123.323867.Commentaries, Editorials and Letters
2023
Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory.
Alvero A, Fox A, Madina B, Krady M, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky T, Rutherford T, Mor G. Immune Modulation of Innate and Adaptive Responses Restores Immune Surveillance and Establishes Antitumor Immunologic Memory. Cancer Immunology Research 2023, 12: 261-274. PMID: 38078853, PMCID: PMC11027955, DOI: 10.1158/2326-6066.cir-23-0127.Peer-Reviewed Original ResearchPD-L1Immunological memoryImmune surveillanceLong-term anti-tumor effectsAnti-tumor immunological memoryAnti-tumor immune responseImmune modulatory capacityAnti-tumor responseOvarian cancer patientsAnti-tumoral responseAnti-tumor effectsImmune regulatory genesSelf-amplifying RNAVirus-like vesiclesPotent CD8MDSC expansionAdaptive armsCurrent immunotherapiesOncolytic capacityPrevent recurrenceAntitumor cytokinesCancer patientsImmune modulationImmune modulatorsOncolytic effectGuidelines on the use of sex and gender in cardiovascular research
Usselman C, Lindsey M, Robinson A, Habecker B, Taylor C, Merryman W, Kimmerly D, Bender J, Regensteiner J, Moreau K, Pilote L, Wenner M, O'Brien M, Yarovinsky T, Stachenfeld N, Charkoudian N, Denfeld Q, Moreira-Bouchard J, Pyle W, DeLeon-Pennell K. Guidelines on the use of sex and gender in cardiovascular research. AJP Heart And Circulatory Physiology 2023, 326: h238-h255. PMID: 37999647, PMCID: PMC11219057, DOI: 10.1152/ajpheart.00535.2023.Peer-Reviewed Original Research